title: Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients.
abstract: The incidence of thromboembolic complications was compared retrospectively in 90 cadaveric kidney allograft recipients treated with cyclosporin and low-dose steroids and the same number of cadaveric kidney allograft recipients treated with azathioprine, antilymphocyte globulin, and high-dose steroids. In the cyclosporin group, 17 thromboembolic complications occurred in 13 patients: 10 pulmonary emboli, 1 renal vein thrombosis, 3 deep vein thromboses, and 3 haemorrhoidal thromboses. In the azathioprine group, the only thromboembolic complication was 1 episode of superficial thrombophlebitis. Haemostatic tests in cyclosporin-treated and azathioprine-treated patients and normal subjects (10 in each group) showed increased concentrations of factor VIII C, fibrinogen, antithrombin III, and protein C in the cyclosporin-treated patients. Adenosine-5'-diphosphate-induced platelet aggregation was also significantly enhanced in the cyclosporin group. The effect of cyclosporin on haemostasis may predispose to thromboembolic complications.
authors.forename: Y
authors.initials: Y
authors.lastname: Vanrenterghem
authors.forename: L
authors.initials: L
authors.lastname: Roels
authors.forename: T
authors.initials: T
authors.lastname: Lerut
authors.forename: J
authors.initials: J
authors.lastname: Gruwez
authors.forename: P
authors.initials: P
authors.lastname: Michielsen
authors.forename: P
authors.initials: P
authors.lastname: Gresele
authors.forename: H
authors.initials: H
authors.lastname: Deckmyn
authors.forename: M
authors.initials: M
authors.lastname: Colucci
authors.forename: J
authors.initials: J
authors.lastname: Arnout
authors.forename: J
authors.initials: J
authors.lastname: Vermylen
mesh_terms: D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D003524:Cyclosporins / Q000009:adverse effects* / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D010974:Platelet Aggregation / Q000187:drug effects; D013923:Thromboembolism / Q000097:blood / Q000139:chemically induced*
chemical_list: D001779:Blood Coagulation Factors; D003524:Cyclosporins; D001379:Azathioprine